Avelumab in combination with axitinib and nivolumab in combination with ipilimumab in the first-line treatment of metastatic renal cell carcinoma: a realworld retrospective cohort study ; Авелумаб в комбинации с акситинибом и ниволумаб в комбинации с ипилимумабом в первой линии терапии метастатического почечно-клеточного рака: ретроспективное когортное исследование реальной практики

Authors: I. V. Tsimafeyeu, O. V. Baklanova, V. A. Chubenko, A. S. Kalpinskiy, S. Z. Safina, A. A. Lebedinets, V. V. Petkau, A. S. Olshanskaya, I. V. Myslevtsev, R. A. Zukov, И. В. Тимофеев, О. В. Бакланова, В. А. Чубенко, А. С. Калпинский, С. З. Сафина, А. А. Лебединец, В. В. Петкау, А. С. Ольшанская, И. В. Мыслевцев, Р. А. Зуков

Contributors: The article was prepared without sponsorship/, Статья подготовлена без спонсорской поддержки.

Source: Malignant tumours; Том 14, № 4 (2024); 9-17 ; Злокачественные опухоли; Том 14, № 4 (2024); 9-17 ; 2587-6813 ; 2224-5057

Subject Terms: метастатический почечно-клеточный рак, nivolumab and ipilimumab, comparison, metastatic renal cell carcinoma, ниволумаб и ипилимумаб, сравнение комбинаций

File Description: application/pdf

Relation: https://www.malignanttumors.org/jour/article/view/1416/1017; Злокачественные новообразования в России в 2022 году (заболеваемость и смертность). Под ред. А.Д. Каприна, В.В. Старинского, О.В. Шахзадовой, И.В. Лисичниковой. М.: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2023.275 с.; Tsimafeyeu I, Aksel E. Renal Cell Carcinoma in the Russian Federation in 2008. Malign Tumours 2010;1:1–4; Tsimafeyeu I, Rahib L. The future landscape of cancer incidence and mortality until 2036 in the Russian Federation. J Clin Oncol 2022;40(16_suppl):e22518-e22518. https://doi.org/10.1200/JCO.2022.40.16_suppl.e22518; Sharp E., Guduru A., May A.M., et al. The distribution of metastatic renal cell carcinoma by presenting tumor stage in the modern era. Clin Genitourin Cancer 2022;20(4):e296-e302. https://doi.org/10.1016/j.clgc.2022.03.001; Tsimafeyeu I., Shatkovskaya O., Krasny S., et al. Overall survival in patients with metastatic renal cell carcinoma in Russia, Kazakhstan, and Belarus: a report from the RENSUR3 registry. Cancer Rep (Hoboken) 2021;4(3):e1331. https://doi.org/10.1002/cnr2.1331; Tsimafeyeu I., Zolotareva T., Varlamov S., et al. Five-year Survival of Patients With Metastatic Renal Cell Carcinoma in the Russian Federation: Results From the RENSUR5 Registry. Clin Genitourin Cancer 2017;15(6):e1069-e1072. https://doi.org/10.1016/j.clgc.2017.07.017; Сафина С.З., Варламов С.А., Снеговой А.В. и соавт. Пятилетняя общая выживаемость больных метастатическим раком почки, получавших эверолимус при прогрессировании на фоне лечения бевацизумабом: проспективное многоцентровое исследование CRAD001LRU02T. Онкоурология 2017;13(4):40–44. https://doi.org/10.17650/1726-9776-2017-13-4-40-44.; Тимофеев И.В., Варламов И.С., Петкау В.В. и соавт. Продолжительность жизни больных метастатическим почечно-клеточным раком в Российской Федерации: результаты многоцентрового регистрового исследования RENSUR3. Злокачественные опухоли. 2019;9(2):45–52. https://doi.org/10.18027/2224-5057-2019-9-2-45-52.; Tsimafeyeu I. Sunitinib in patients with metastatic renal cell carcinoma with favorable risk: be aware of PD-L1 expression. Med Sci (Basel) 2024;12(3):48. https://doi.org/10.3390/medsci12030048; Волкова М.И., Носов Д.А., Алексеев Б.Я. и соавт. Почечноклеточный рак. Практические рекомендации RUSSCO, часть 1.2. Злокачественные опухоли 2024;14(3s2):207–220. https://doi.org/10.18027/2224-5057-2024-14-3s2-1.2-08.; Тимофеев И.В. Ниволумаб: 5 лет со дня международной регистрации иммунотерапии метастатического рака почки. Злокачественные опухоли. 2020;10(4):21–29. https://doi.org/10.18027/2224-5057-2020-10-4-21-29.; Резолюция по итогам Совета экспертов на тему «Авелумаб + акситиниб в 1-й линии терапии пациентов с метастатическим почечно-клеточным раком. Результаты общей выживаемости в исследовании JAVELIN Renal 101». Онкоурология 2024;20(3):00–00.; Tannir N.M., Albigès L., McDermott D.F., et al. Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 8-year follow-up results of efficacy and safety from the phase III CheckMate 214 trial. Ann Oncol 2024;35(11):1026–1038. https://doi.org/10.1016/j.annonc.2024.07.727; Motzer R.J., Penkov K., Uemura K., et al. Avelumab + axitinib vs sunitinib in patients (pts) with advanced renal cell carcinoma (aRCC): Final overall survival (OS) analysis from the JAVELIN Renal 101 phase 3 trial. J Clin Oncol 2024;42(16):4508–4508. https://doi.org/10.1200/JCO.2024.42.16_suppl.450; Носов Д.А., Ворошилова Е.А., Саяпина М.С. Современное представление об алгоритме лекарственного лечения и оптимальной последовательности использования таргетных препаратов. Онкоурология 2014;10(3):12–21. https://doi.org/10.17650/1726-9776-2014-10-3-12-21.; Motzer R.J., Tannir N.M., McDermott D.F., et al. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N Engl J Med. 2018 Apr 5;378(14):1277–1290. https://doi.org/10.1056/NEJMoa1712126; Motzer R.J., Penkov K., Haanen J., et al. Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med 2019;380(12):1103–1115. https://doi.org/10.1056/NEJMoa1816047; Kato T., Nakano Y., Hongo F., et al. Real-world outcomes of avelumab plus axitinib as first-line therapy in patients with advanced renal cell carcinoma in Japan: A multicenter, retrospective, observational study (J-DART). Int J Urol 2024;31(3):265–272. https://doi.org/10.1111/iju.15345; Nathan P. D, Charnley N., Frazer R., et al. A UK real-world observational study of avelumab + axitinib (A + Ax) in advanced renal cell carcinoma (aRCC): Outcomes at 36 months post treatment initiation. J Clin Oncol 2024;42:386–386; Ishihara H., Yuki N., Ishiyama R., et al. Real-world outcomes of nivolumab plus ipilimumab combination therapy for advanced renal cell carcinoma in Japanese patients: data with a minimum of 3 years of follow-up. Jpn J Clin Oncol 2024;54(5):577–583. https://doi.org/10.1093/jjco/hyae001; Beltran-Bless A.A., Shrem N.S., Ghosh S., et al. Real-world efficacy and toxicity of ipilimumab and nivolumab as first line treatment of metastatic renal cell carcinoma (mRCC) in a subpopulation of elderly and poor performance status patients. J Clin Oncol 2024;42(4):367–367. https://doi.org/10.1200/JCO.2024.42.4_suppl.367; Tomita Y., Motzer R.J., Choueiri T.K., et al. Efficacy of avelumab plus axitinib versus sunitinib by numbers of IMDC risk factors and target tumor sites at baseline in advanced renal cell carcinoma: long-term follow-up results from JAVELIN Renal 101. ESMO Open 2023;8(6):102034. https://doi.org/10.1016/j.esmoop.2023.102034; Albiges L., Tannir N.M., Burotto M., et al. Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial. ESMO Open 2020;5(6):e001079. https://doi.org/10.1136/esmoopen-2020-001079; Geynisman D.M., Chan P., Robert N., et al. 1465P - Real-world (RW) outcomes in metastatic renal cell carcinoma (mRCC) patients treated with first-line (1L) nivolumab plus ipilimumab (NIVO + IPI) in the United States. Ann of Oncol 2022;33:(suppl_7):S660-S680.10.1016/annonc/annonc1072S1216-S1216. https://doi.org/10.1016/j.annonc.2022.07.1568; Doshi G.K., Robert N.J., Chen L., et al. Real-world outcomes in patients with metastatic renal cell carcinoma treated with first-line nivolumab plus ipilimumab. J Clin Oncol2021;39(28):305–305. https://doi.org/10.1200/JCO.2020.39.28_suppl.305; Shah N.J., Sura S.D., Shinde R., et al. Real-world clinical outcomes of patients with metastatic renal cell carcinoma receiving pembrolizumab + axitinib vs. ipilimumab + nivolumab. Urol Oncol 2023;41(11):459.e1–459.e8. https://doi.org/10.1016/j.urolonc.2023.08.009; Kato T, Furukawa J, Hinata N, et al. Real-world outcomes of avelumab plus axitinib in patients with advanced renal cell carcinoma in Japan: long-term follow-up from the J-DART2 retrospective study. Int J Clin Oncol. 2024 Nov 16. doi:10.1007/s10147-024-02618-9. Epub ahead of print. PMID: 39549218; Chubenko V., Baklanova O., Kalpinskiy A., et al. Avelumab plus axitinib for first-line treatment of advanced renal cell carcinoma: A real-world ambispective RAVE-Renal study. J Clin Oncol 2024;42(23_suppl.). https://doi.org/10.1200/JCO.2024.42.23_suppl.117; Tsimafeyeu I., Chubenko V., Baklanova O., et al. Real-World Efficacy and Safety of Avelumab Plus Axitinib in Metastatic Renal Cell Carcinoma: Results from the Ambispective RAVE-Renal Study. Current Oncology 2025;32(1):11. https://doi.org/10.3390/curroncol32010011.; https://www.malignanttumors.org/jour/article/view/1416

Availability: https://www.malignanttumors.org/jour/article/view/1416
https://doi.org/10.18027/2224-5057-2024-032

First experience of using Pembroria® medication in patients with disseminated renal cell carcinoma ; Первый опыт применения препарата Пемброриа® у пациентов с диссеминированным почечно-клеточным раком

Authors: I. M. Shevchuk, N. D. Movchan, И. М. Шевчук, Н. Д. Мовчан

Source: Cancer Urology; Том 19, № 4 (2023); 44-51 ; Онкоурология; Том 19, № 4 (2023); 44-51 ; 1996-1812 ; 1726-9776

Subject Terms: акситиниб, Pembroria®, biosimilar, metastatic renal cell carcinoma, lenvatinib, axitinib, Пемброриа®, биосимиляр, метастатический почечно-клеточный рак, ленватиниб

File Description: application/pdf

Relation: https://oncourology.abvpress.ru/oncur/article/view/1787/1504; Рак паренхимы почки. Клинические рекомендации 2023 г. Доступно по: https://oncology-association.ru/wp-content/uploads/2023/11/rak-pochki_23.pdf.; Powles T., Albiges L., Bex A. et al. ESMO Clinical Practice Guideline update on the use of immunotherapy in early stage and advanced renal cell carcinoma. Ann Oncol 2021;32(12):1511–9. DOI:10.1016/j.annonc.2021.09.014; Motzer R., Jonasch E., Agarwal N. et al. Kidney Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 2022;20(1):71–90. DOI:10.6004/jnccn.2022.0001; Ljungberg B., Albiges L., Abu-Ghanem Y. et al. European Association of Urology Guidelines on Renal Cell Carcinoma: The 2019 Update. Eur Urol 2019;75(5):799–810. DOI:10.1016/j.eururo.2019.02.011; Powles T., Plimack E.R., Soulières D. et al. Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial [published correction appears in Lancet Oncol 2020;21(12):e553]. Lancet Oncol 2020;21(12):1563–73. DOI:10.1016/S1470-2045(20)30436-8; Motzer R.J., Porta C., Eto M. et al. Phase 3 trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) or everolimus (EVE) versus sunitinib (SUN) monotherapy as a first-line treatment for patients (pts) with advanced renal cell carcinoma (RCC) (CLEAR study). J Clin Oncol 2021;39(suppl 6):269. DOI:10.1200/JCO.2021.39.6_suppl.269; Инструкция по применению медицинского препарата Пемброриа. Доступно по: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=b50afaa4-67c8-4d9c-9392-366a3322a7ec.; Eisenhauer E.A., Therasse P., Bogaerts J. et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45(2):228–47. DOI:10.1016/j.ejca.2008.10.026; Heng D.Y., Xie W., Regan M.M. et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol 2009;27:5794–9. DOI:10.1200/JCO.2008.21.4809; Grünwald V. Poster presented at the ASCO Annual Meeting; 04–08 June, 2021; Virtual Format; abstract #4560. J Clin Oncol 2021;39:15_suppl:4560.; Rini B., Plimack E., Stus V. et al. Pembrolizumab plus axitinib versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma: 5-year analysis of KEYNOTE-426. J Clin Oncol 2023;41(suppl 17):abstr LBA4501. DOI:10.1200/JCO.2023.41.17_suppl.LBA450; Motzer R., Porta C., Alekseev B. et al. Health-related quality-of-life outcomes in patients with advanced renal cell carcinoma treated with lenvatinib plus pembrolizumab or everolimus versus sunitinib (CLEAR): a randomised, phase 3 study. Lancet Oncol 2022;23(6):768–80. DOI:10.1016/S1470-2045(22)00212-1; https://oncourology.abvpress.ru/oncur/article/view/1787

Availability: https://oncourology.abvpress.ru/oncur/article/view/1787
https://doi.org/10.17650/1726-9776-2023-19-4-44-51

Efficacy and safety of cabozantinib in metastatic renal cell carcinoma patients: Russian multicenter observational study ; Эффективность и безопасность кабозантиниба у пациентов с распространенным почечно-клеточным раком: российское многоцентровое наблюдательное исследование

Authors: M. I. Volkova, A. S. Kalpinskiy, K. V. Men'shikov, L. V. Gorbuleva, O. I. Evsyukova, V. R. Meltonyan, S. V. Mishugin, M. R. Maturov, A. S. Ol'shanskaya, D. Yu. Shemetov, T. A. Sannikova, M. V. Makhnutina, M. A. Filip'eva, E. A. Gaysina, E. G. Ovchinnikova, V. B. Matveev, B. Ya. Alekseev, М. И. Волкова, А. С. Калпинский, К. В. Меньшиков, Л. В. Горбулева, О. И. Евсюкова, В. Р. Мелтонян, С. В. Мишугин, М. Р. Матуров, А. С. Ольшанская, Д. Ю. Шеметов, Т. А. Санникова, М. В. Махнутина, М. А. Филипьева, Е. А. Гайсина, Е. Г. Овчинникова, В. Б. Матвеев, Б. Я. Алексеев

Source: Cancer Urology; Том 19, № 1 (2023); 46-60 ; Онкоурология; Том 19, № 1 (2023); 46-60 ; 1996-1812 ; 1726-9776

Subject Terms: терапия 2-й линии, metastatic renal cell carcinoma, first-line therapy, second-line therapy, метастатический почечно-клеточный рак, терапия 1-й линии

File Description: application/pdf

Relation: https://oncourology.abvpress.ru/oncur/article/view/1693/1440; Состояние онкологической помощи населению России в 2021 году. Под ред. А.Д. Каприна, В.В. Старинского, А.О. Шахзадовой. М.: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2022. 239 с.; Волкова М.И. Стратегия хирургического лечения больных локализованным и местно-распространенным раком почки. Дис. … д-ра мед. наук. М., 2014.; Волкова М.И., Алексеев Б.Я., Гладков О.А. и др. Практические рекомендации по лекарственному лечению почечно-клеточного рака. Злокачественные опухоли: Практические рекомендации RUSSCO 2022;12(3s2):579–88. DOI:10.18027/2224-5057-2022-12-3s2-579-588; Choueiri T.K., Halabi S., Sanford B.L. et al. Cabozantinib versus sunitinib as initial targeted therapy for patients with metastatic renal cell carcinoma of poor or intermediate risk: the alliance A031203 CABOSUN Trial. J Clin Oncol 2017;35(6):591-7. DOI:10.1200/JCO.2016.70.7398; Pal S.K., Tangen C., Thompson Y.M. et al. Sunitinib versus cabozantinib, crizotinib or savolitinib in metastatic papillary renal cell carcinoma (pRCC): Results from the randomized phase II SWOG 1500 study. J Clin Oncol 2021;39(6_suppl):270.; Choueiri T.K., Escudier B., Powles T. et al. Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial. Lancet Oncol 2016;17(7):917-27. DOI:10.1016/S1470-2045(16)30107-3; Choueiri T.K., Powles T., Burotto M. et al. Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med 2021;384(9):829–41. DOI:10.1056/NEJMoa2026982; Инструкция по медицинскому применению препарата кабозантиниб. Регистрационный номер: ЛП-005558-300519 (изм. № 3 к ЛП-005558-300519).; Eisenhauer E.A., Therasse P., Bogaerts J. et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45(2):228-47. DOI:10.1016/j.ejca.2008.10.0260.; http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm.; Boustany J., Abdessater M., Hachem C.E. et al. Recurrent metastatic clear cell renal carcinoma with sarcomatoid dedifferentiation treated with surgery and cabozantinib. Oncotarget 2020;11(20):1922-8. DOI:10.18632/oncotarget.27543; Liu Y., Zhou L., Chen Y. et al. Hypertension as a prognostic factor in metastatic renal cell carcinoma treated with tyrosine kinase inhibitors: a systematic review and meta-analysis. BMC Urol 2019;19(1):49. DOI:10.1186/s12894-019-0481-5; https://oncourology.abvpress.ru/oncur/article/view/1693

Availability: https://oncourology.abvpress.ru/oncur/article/view/1693
https://doi.org/10.17650/1726-9776-2023-19-1-46-60

Сорафениб в последовательной терапии метастатического рака почки

Source: Медицинский совет, Vol 0, Iss 5-6, Pp 86-90 (2019)

Subject Terms: метастатический почечно-клеточный рак, 03 medical and health sciences, нексавар, 0302 clinical medicine, ингибиторы тирозинкиназ, сорафениб, Medicine, таргетная терапия

Access URL: https://www.med-sovet.pro/jour/article/download/3625/3240
https://doaj.org/article/f4030d9684c7497db6a7564c667d9905
https://www.med-sovet.pro/jour/article/viewFile/3625/3240

Experience of using 1st line combination immunotherapy in patients with metastatic renal cell carcinoma ; Опыт применения комбинированной иммунотерапии в 1-й линии у больных метастатическим почечно-клеточным раком

Authors: A. S. Kalpinskiy, I. V. Myslevtsev, A. N. Andrianov, K. M. Nyushko, M. P. Golovashchenko, N. V. Vorobiev, Ya. L. Chertkova, I. Kh. Shirukova, E. Yu. Usanova, B. Ya. Alekseev, А. С. Калпинский, И. В. Мыслевцев, А. Н. Андрианов, К. М. Нюшко, М. П. Головащенко, Н. В. Воробьев, Я. Л. Черткова, И. Х. Ширукова, Е. Ю. Усанова, Б. Я. Алексеев

Source: Cancer Urology; Том 17, № 3 (2021); 47-63 ; Онкоурология; Том 17, № 3 (2021); 47-63 ; 1996-1812 ; 1726-9776

Subject Terms: иммунотаргетная комбинация, ipilimumab, renal cell carcinoma, metastatic renal cell carcinoma, immuno-oncological combination, immunotarget combination, ипилимумаб, почечно-клеточный рак, метастатический почечно-клеточный рак, иммуноонкологическая комбинация

File Description: application/pdf

Relation: https://oncourology.abvpress.ru/oncur/article/view/1516/1298; GLOBOCAN: cancer incidence and mortality worldwide in 2020. Available at: http://gco.iarc.fr/.; Злокачественные новообразования в России в 2019 году (заболеваемость и смертность). Под ред. А.Д. Каприна, В.В. Старинского, А.О. Шахзадовой. М.: МНИОИ им. ПА. Герцена - филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2020. 214 с.; Клинические рекомендации Минздрава России «Рак паренхимы почки». 2021. Доступно по: https://cr.minzdrav.gov.ru/recomend/10_2.; Клинические рекомендации Ассоциации онкологов России «Рак паренхимы почки». 2020. Доступно по: https://oncology-association.ru/clinical-guidelines.; National Comprehensive Cancer Network, Inc. The NCCN Clinical Practice Guidelines in Oncology for Kidney Cancer, version 2.2022. Available at: https://www.nccn.org/guidelines/nccn-guidelines/guidelines-detail?category=1&id=1440.; Escudier B., Porta C., Schmidinger M. et al. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2019;30(5):706—20. DOI:10.1093/annonc/mdz056.; Bedke J., Albiges L., Capitanio U. et al. The 2021 Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Immune Checkpoint Inhibitor-based Combination Therapies for Treatment-naive Metastatic Clear-cell Renal Cell Carcinoma Are Standard of Care. Eur Urol 2021;80(4):393—7. DOI:10.1016/j.eururo.2021.04.042.; Rini B.I., Plimack E.R., Stus V. et al. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med 2019;380(12):1116—27. DOI:10.1056/NEJMoa1816714.; Powles T., Plimack E.R., Soulieres D. et al. Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial. Lancet Oncol 2020;21(12):1563—73. DOI:10.1016/S1470-2045(20)30436-8.; Rini B.I., Plimack E.R., Stus V. et al. Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma (ccRCC): results from 42-month follow-up of KEYNOTE-426. J Clin Oncol 2021; 39(15_suppl):4500.; Choueiri T.K., Motzer R.J., Rini B.I. et al. Updated efficacy results from the JAVELIN Renal 101 trial: First-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma. Ann Oncol 2020;31(8):1030—1039. DOI:10.1016/j.annonc.2020.04.010.; Apolo A.B., Powles T., Burotto M. et al. Nivolumab plus cabozantinib (N + C) versus sunitinib (S) for advanced renal cell carcinoma (aRCC): outcomes by baseline disease characteristics in the phase 3 CheckMate 9ER trial. J Clin Oncol 2021;39(15_suppl):4553.; Motzer R., Alekseev B., Rha S.Y. et al. Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma. N Engl J Med 2021;384(14):1289—300. DOI:10.1056/NEJMoa2035716.; Motzer R.J., Tannir N.M., McDermott D.F. et al. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N Engl J Med 2018;378(14):1277—90. DOI:10.1056/NEJMoa1712126.; Albiges L., Tannir N.M., Burotto M. et al. Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial. ESMO Open 2020;5(6):e001079. DOI:10.1136/esmoopen-2020-001079.; Motzer R., Tannir N., McDermott D. et al. Conditional survival and 5-year follow-up in CheckMate 214: first-line nivolumab plus ipilimumab versus sunitinib in advanced renal cell carcinoma. Presented at: European Society for Medical Oncology Congress, September 16—21, 2021; virtual. Abstract 661P.; Eisenhauer E.A., Therasse P., Bogaerts J. et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45(2):228—47. DOI:10.1016/j.ejca.2008.10.026.; http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm.; Tykodi S.S., Gordan L.N., Alter R.S. et al. Nivolumab plus ipilimumab in patients with advanced non-clear cell renal cell carcinoma (nccRCC): safety and efficacy from CheckMate 920. J Clin Oncol 2021;39(6_suppl):309.; Emamekhoo H., Olsen M.R., Carthon B.C. et al. Safety and efficacy outcomes with nivolumab plus ipilimumab in patients with advanced renal cell carcinoma and brain metastases: results from the CheckMate 920 trial. J Clin Oncol 2021;39(15_suppl):4515.; https://oncourology.abvpress.ru/oncur/article/view/1516

Availability: https://oncourology.abvpress.ru/oncur/article/view/1516
https://doi.org/10.17650/1726-9776-2021-17-3-47-63

The role of sunitinib in the therapy of metastatic renal cell carcinoma ; Сунитиниб в терапии метастатического почечно-клеточного рака

Authors: I. G. Rusakov, A. A. Gritskevich, T. P. Baitman, A. N. Shipilova, S. V. Mishugin, И. Г. Русаков, А. А. Грицкевич, Т. П. Байтман, А. Н. Шипилова, С. В. Мишугин

Source: Meditsinskiy sovet = Medical Council; № 9 (2020); 136-145 ; Медицинский Совет; № 9 (2020); 136-145 ; 2658-5790 ; 2079-701X

Subject Terms: метастатический почечно-клеточный рак, angiogenesis inhibitors, tyrosine kinase inhibitors, immunotherapy, metastatic renal cell carcinoma, ингибиторы ангиогенеза, ингибиторы рецепторов тирозинкиназ, иммунотерапия

File Description: application/pdf

Relation: https://www.med-sovet.pro/jour/article/view/5717/5215; Каприн А.Д., Старинский В.В., Петрова Г.В. (ред.) Злокачественные новообразования в России в 2018 году (заболеваемость и смертность). М.: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИЦ радиологии» Минздрава России; 2019. 250 с. Режим доступа: https://oncology-association.ru/files/medstat/2018.pdf.; Каприн А.Д., Старинский В.В., Петрова Г.В. (ред.) Состояние онкологической помощи населению России в 2018 году. М.: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИЦ радиологии» Минздрава России; 2019. 236 с. Режим доступа: https://nnood.ru/wp-content/uploads/2019/04/ Statichticheskijj-ezhegodnik-Gercena-2018.pdf.; Adashek J.J., Aydin A.M., Kim P., Spiess P.E. The role of metastasectomy in the treatment of metastatic renal cell carcinoma. AME Med J. 2019;4:30– 41. doi:10.21037/amj.2019.06.02.; Martínez-Salamanca J.I., Linares E., González J., Bertini R., Carballido J.A., Chromecki T. et al. Lessons learned from the International Renal Cell Carcinoma-Venous Thrombus Consortium (IRCC-VTC). Curr Urol Rep. 2014;15:404. doi:10.1007/s11934-014-0404-7.; Волкова М.И., Климов А.В., Черняев В.А. Паллиативная нефрэктомия: все ли больные нуждаются в операции? Злокачественные опухоли. 2016;(4–1):115–118. Режим доступа: https://www.malignanttumors.org/ jour/article/view/299/269.; Yagoda A., Abi-Rached B., Petrylak D. Chemotherapy for advanced renalcell carcinoma: 1983–1993. Semin Oncol. 1995;22(1):42–60. Available at: https://pubmed.ncbi.nlm.nih.gov/7855619/; Ljungberg B., Hanbury D.C., Kuczyk M.A., Merseburger A.S., Mulders P.F., Patard J.J., Sinescu I.C. Renal Cell Carcinoma Guideline. European Urology. 2007;51(6):1502–1510. doi:10.1016/j.eururo.2007.03.035.; Русаков И.Г. Вторая линия таргетной терапии больных с метастатическим раком почки. Экспериментальная и клиническая урология. 2011;(2– 3):114–115. Режим доступа: https://ecuro.ru/article/vtoraya-liniyatargetnoi-terapii-bolnykh-s-metastaticheskim-rakom-pochki.; Ljungberg B., Albiges L., Abu-Ghanem Y., Bensalah K., Dabestani S., FernándezPello S. et al. European Association of Urology guidelines on renal cell carcinoma: the 2019 update. Eur Urol. 2019;75:799–810. doi:10.1016/j.eururo.2019.02.011.; Деньгина Н.В., Митин Т.В., Гамаюнов С.В., Сафина С.З., Крейнина Ю.М., Тимофеев И.В. Стереотаксическая лучевая терапия экстракраниальных метастазов почечно-клеточного рака в комбинации с ингибиторами тирозинкиназы и иммунотерапией: первые результаты клинического исследования ib фазы (VOLGA STUDY). Злокачественные опухоли. 2019;9(3):57–64. doi:10.18027/2224-5057-2019-9-3-57-64.; Elhilali M.M., Gleave M., Fradet Y., Davis I., Venner P., Saad F. et al. Placeboassociated remissions in a multicentre, randomized, double-blind trial of interferon gamma-1b for the treatment of metastatic renal cell carcinoma. BJU Int. 2000;86(6):613–617. doi:10.1046/j.1464-410x.2000.00880.x.; Flanigan R.C., Salmon S.E., Blumenstein B.A., Bearman S.I., Roy V., McGrath P.C. et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med. 2001;345:1655–1659. doi:10.1056/NEJMoa003013.; Mickisch G.H., Garin A., van Poppel H., Prigck L., Sylvester R. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet. 2001;358(9286):966–970. doi:10.1016/s0140-6736(01)06103-7.; Rezaei N., Keshavarz-Fathi M. (eds.) Vaccines for Cancer Immunotherapy. An Evidence­Based Review on Current Status and Future Perspectives. 1st ed. Academic Press; 2018. 198 p. Available at: https://www.elsevier.com/ books/vaccines-for-cancer-immunotherapy/rezaei/978-0-12-814039-0.; Eisen T., Christmas T. (eds.). Сlinical progress in renal cancer. London, CRC Press; 2007. 224 р. doi:10.3109/9780203931615.; Демидов Л.В., Харкевич Г.Ю., Тимофеев И.В. Уcпехи и неудачи применения цитокинов в лекарственной терапии некоторых солидных опухолей. Практическая онкология. 2003;4(5):140–147. Режим доступа: https:// rosoncoweb.ru/library/journals/practical_oncology/arh015/03.pdf.; Bekisz J., Baron S., Balinsky C., Morrow A., Zoon K.C. Antiproliferative Properties of Type I and Type II Interferon. Pharmaceuticals. 2010;3(4):994– 1015. doi:10.3390/ph3040994.; Rosenberg S.A., Lotze M.T., Muul L.M., Leitman S., Chang A.E., Ettinghausen S.E. et al. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med. 1985;313(23):1485–1492. doi:10.1056/NEJM198512053132327.; Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med. 1971;285(21):1182–1186. doi:10.1056/NEJM197111182852108.; Mukherjee A., Madamsetty V.S., Paul M.K., Mukherjee S. Recent Advancements of Nanomedicine towards Antiangiogenic Therapy in Cancer. Int J Mol Sci. 2020;21(2):455. doi:10.3390/ijms21020455.; Singer E.A., Gupta G.N., Srinivasan R. Targeted Therapeutic Strategies for the Management of Renal Cell Carcinoma. Curr Opin Oncol. 2012;24(3):284–290. doi:10.1097/CCO.0b013e328351c646.; Moore L.E., Nickerson M.L., Brennan P., Toro J.R., Jaeger E., Rinsky J. et al. Von Hippel-Lindau (VHL) inactivation in sporadic clear cell renal cancer: associations with germline VHL polymorphisms and etiologic risk factors. PLoS Genet. 2011;7(10):e1002312. doi:10.1371/journal.pgen.1002312.; Kamura T., Sato S., Iwai K., Czyzyk-Krzeska M., Conaway R.C., Conaway J.W. Activation of HIF1alpha ubiquitination by a reconstituted von Hippel Lindau (VHL) tumor suppressor complex. Proc Natl Acad Sci USA. 2011;97(19):10430–10435. doi:10.1073/pnas.190332597.; Калпинский А.С., Алексеев Б.Я. Эффективность Сунитиниба в таргетной терапии метастатического рака почки. Онкоурология. 2009;5(3):63–67. doi:10.17650/1726-9776-2009-5-3-63-67.; Mukherjee S., Patra C.R. Therapeutic application of anti-angiogenic nanomaterials in cancers. Nanoscale. 2016;(25):12444–12470. doi:10.1039/c5nr07887c.; Mendel D.B., Laird A.D., Xin X., Louie S.G., Christensen J.G., Li G. et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res. 2003;9(1):327–337. Available at: https://clincancerres.aacrjournals.org/content/9/1/327.long.; Abrams T.J., Lee J.B., Murray L.J., Pryer N.K., Cherrington J.M. SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. Mol Cancer Ther. 2003;2(5):471– 478. Available at: https://mct.aacrjournals.org/content/2/5/471.long.; Abrams T.J., Murray L.J., Pesenti E., Holway V.W., Colombo T., Lee L.B. et al. Preclinical evaluation of the tyrosine kinase inhibitor SU11248 as a single agent and in combination with “standard of care” therapeutic agents for the treatment of breast cancer. Mol Cancer Ther. 2003;2(10):1011–1021. Available at: https://mct.aacrjournals.org/content/2/10/1011.long.; Murray L.J., Abrams T.J., Long K.R., Ngai T.J., Olson L.M., Hong W. et al. SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model. Clin Exp Metastasis. 2003;20:757–766. doi:10.1023/b:clin.0000006873.65590.68.; Morimoto A.M., Tan N., West K., McArthur G., Toner G.C., Manning W.C. et al. Gene expression profiling of human colon xenograft tumors following treatment with SU11248, a multitargeted tyrosine kinase inhibitor. Oncogene. 2004;23:1618–1626. doi:10.1038/sj.onc.1207268.; Yee K.W., Schittenhelm M., O’Farrell A.M., Town A.R., McGreevey L., Bainbridge T. et al. Synergistic effect of SU11248 with cytarabine or daunorubicin on FLT3 ITD-positive leukemic cells. Blood. 2004;104(13):4202– 4209. doi:10.1182/blood-2003-10-3381.; Baratte S., Sarati S., Frigerio E., James C.A., Ye C., Zhang Q. Quantitation of SU11248, an oral multi-target tyrosine kinase inhibitor, and its metabolite in monkey tissues by liquid chromatograph with tandem mass spectrometry following semi-automated liquid-liquid extraction. J Chromatogr A. 2004;1024(1–2):87–94. doi:10.1016/j.chroma.2003.10.085.; Le Tourneau C., Raymond E., Faivre S. Sunitinib: a novel tyrosine kinase inhibitor. A brief review of its therapeutic potential in the treatment of renal carcinoma and gastrointestinal stromal tumors (GIST). Ther Clin Risk Manag. 2007;3(2):341–348. doi:10.2147/tcrm.2007.3.2.341.; Faivre S., Delbaldo C., Vera K., Robert C., Lozahic S., Lassau N. et al. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol. 2006;24(1):25–35. doi:10.1200/JCO.2005.02.2194.; Motzer R.J., Bacik J., Schwartz L.H., Reuter V., Russo P., Marion S., Mazumdar M. Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol. 2004;22(3):454–463. doi:10.1200/JCO.2004.06.132.; Motzer R.J., Rini B.I., Bukowski R.M., Curti B.D., George D.J., Hudes G.R. et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA. 2006;295(21):2516–2524. doi:10.1001/jama.295.21.2516.; Motzer R.J., Michaelson M.D., Redman B.G., Hudes G.R., Wilding G., Figlin R.A. et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol. 2006;24(1):16–24. doi:10.1200/JCO.2005.02.2574.; Deprimo S.E., Bello C.L., Smeraglia J., Baum C.M., Spinella D., Michaelson D., Motzer R.J. Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins. J Transl Med. 2007;5:32. doi:10.1186/1479-5876-5-32.; Motzer R.J., Hutson T.E., Tomczak P., Michaelson M.D., Bukowski R.M., Rixe O. et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007;356:115–124. doi:10.1056/NEJMoa065044.; Kollmannsberger C., Soulieres D., Wong R., Scalera A., Gaspo R., Bjarnason G. Sunitinib therapy for metastatic renal cell carcinoma: recommendations for management of side effects. Can Urol Ass J. 2007;1(2S):41–54. doi:10.5489/cuaj.67.; Баныра О.Б., Шуляк А.В. Блокада ангиогенеза в терапии рака почки: механизмы, особенности и перспективы. Экспериментальная и клиническая урология. 2011;(1):59–67. Режим доступа: https://ecuro.ru/sites/default/files/10_1.pdf.; Qin S., Li A., Yi M., Yu S., Zhang M., Wu K. Recent advances on anti-angiogenesis receptor tyrosine kinase inhibitors in cancer therapy. Journal of Hematology & Oncology. 2019;12:27. doi:10.1186/s13045-019-0718-5.; Lugano R., Ramachandran M., Dimberg A. Tumor angiogenesis: causes, consequences, challenges and opportunities. Cell Mol Life Sci. 2020;77:1745–1770. doi:10.1007/s00018-019-03351-7.; Kuo C.J. Overview of angiogenesis inhibitors. UpToDate. Apr 2020:1–11. Available at: https://www.uptodate.com/contents/overview-of-angiogenesis-inhibitors/print.; Dufies M., Giuliano S., Ambrosetti D., Claren A., Ndiaye P.D., Mastri M. et al. Sunitinib stimulates expression of VEGFC by tumor cells and promotes lymphangiogenesis in clear cell renal cell carcinomas. Cancer Res. 2017;77(5):1212–1226. doi:10.1158/0008-5472.CAN-16-3088.; Deleuze A., Saout J., Dugay F., Peyronnet B., Mathieu R., Verhoes G. et al. Immunotherapy in Renal Cell Carcinoma: The Future Is Now. Int J Mol Sci. 2020;21(7):2532. doi:10.3390/ijms21072532.; Bjarnason G.A., Khalil B., Hudson J.M., Williams R., Milot L.M., Atri M. et al. Outcomes in patients with metastatic renal cell cancer treated with individualized sunitinib therapy: correlation with dynamic microbubble ultrasound data and review of the literature. Urol Oncol. 2014;32(4):480–487. doi:10.1016/j.urolonc.2013.10.004.; Atkinson B.J., Kalra S., Wang X., Bathala T.K., Corn P., Tannir N.M., Jonasch E. Clinical outcomes for patients with metastatic renal cell carcinoma treated with alternative sunitinib schedules. J Urol. 2014;191(3):611–618. doi:10.1016/j.juro.2013.08.090.; Najjar Y.G., Mittal K., Elson P., Wood L., Garcia J.A., Dreicer R., Rini B.I. A 2 weeks on and 1 week off schedule of sunitinib is associated with decreased toxicity in metastatic renal cell carcinoma. Eur J Cancer. 2014;50(6):1084–1089. doi:10.1016/j.ejca.2014.01.025.; Lee J.L., Kim M.K., Park I., Ahn J.H., Lee D.H., Ryoo H.M. et al. Randomizеd phase II trial of sunitinib four weeks on and two weeks off versus two weeks on and one week off in metastatic clear-cell type rеnal cell carcinoma: RESTORE trial. Ann Oncol. 2015;26(11):2300–2305. doi:10.1093/annonc/mdv357.; Bracarda S., Iacovelli R., Boni L., Rizzo M., Derosa L., Rossi M. et al. Sunitinib administered on 2/1 schedule in patients with metastatic renal cell carcinoma: the RAINBOW analysis. Ann Oncol. 2016;27:366. doi:10.1093/annonc/mdv589.; Hutson T.E., Bukowski R.M., Rini B.I., Larkin J.M., Figlin R.A. et al. Efficacy and safety of sunitinib in elderly patients with metastatic renal cell carcinoma. Br J Cancer. 2014;110(5):1125–1132. doi:10.1038/bjc.2013.832.; Miyake H., Miyazaki A., Harada K., Fujisawa M. Assessment of efficacy, safety and quality of life of 110 patients treated with sunitinib as first-line therapy for metastatic renal cell carcinoma: experience in real-world clinical practice in Japan. Med Oncol. 2014;31:978. doi:10.1007/s12032-014-0978-4.; Pan X., Huang H., Huang Y., Liu B., Cui X., Gan S. et al. Sunitinib dosing schedule 2/1 improves tolerability, efficacy, and healthrelated quality of life in Chinese patients with metastatic renal cell carcinoma. Urol Oncol. 2015;33(268):e9–15. doi:10.1016/j.urolonc.2015.03.008.; Sheng X., Chi Z., Cui C., Si L., Li S., Tang B. et al. Efficacy and safety of sorafenib versus sunitinib as first-line treatment in patients with metastatic renal cell carcinoma: largest single-center retrospective analysis. Oncotarget. 2016;7:27044–27054. doi:10.18632/oncotarget.7395.; Tan H.S., Li H., Hong Y.W., Toh C.K., Wong A., Lopes G. et al. Efficacy and safety of an attenuated-dose sunitinib regimen in metastatic renal cell carcinoma: results from a prospective registry in singapore. Clin Genitourin Cancer. 2015;13(4):e285–295. doi:10.1016/j.clgc.2014.11.004.; Zhang H.L., Sheng X.N., Li X.S., Wang H.K., Chi Z.H., He Z.S. et al. Sorafenib versus sunitinib as first-line treatment agents in Chinese patients with metastatic renal cell carcinoma: the largest multicenter retrospective analysis of survival and prognostic factors. BMC Cancer. 2017;17:16. doi:10.1186/s12885-016-3016-4.; Guo J., Jin J., Oya M., Uemura H., Takahashi S., Tatsugami K. et al. Safety of pazopanib and sunitinib in treatment-naive patients with metastatic renal cell carcinoma: Asian versus non-Asian subgroup analysis of the COMPARZ trial. J Hematol Oncol. 2018;11:69. doi:10.1186/s13045-018-0617-1.; Носов Д.А., Волкова М.И., Гладков О.А., Попов А.М, Харкевич Г.Ю. Практические рекомендации по лекарственному лечению почечноклеточного рака. Злокачественные опухоли. 2019;9(3s2):498–506. Режим доступа: https://rosoncoweb.ru/standarts/RUSSCO/2019/2019-30.pdf.; Armstrong A.J., Halabi S., Eisen T., Broderick S., Stadler W.M., Jones R.J. et al. Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial. Lancet Oncol. 2016;17(3):378–388. doi:10.1016/S1470-2045(15)00515-X.; Tannir N.M., Jonasch E., Albiges L., Altinmakas E., Ng C.S., Matin S.F. et al. Everolimus Versus Sunitinib Prospective Evaluation in Metastatic NonClear Cell Renal Cell Carcinoma (ESPN): A Randomized Multicenter Phase 2 Trial. Eur Urol. 2016;69(5):866–874. doi:10.1016/j.eururo.2015.10.049.; Knox J.J., Barrios C.H., Kim T.M., Cosgriff T., Srimuninnimit V., Pittman K. et al. Final overall survival analysis for the phase II RECORD-3 study of firstline everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC. Ann Oncol. 2017;28(6):1339–1345. doi:10.1093/annonc/mdx075.; Motzer R.J., Barrios C.H., Kim T.M., Falcon S., Cosgriff T., Harker W.G. et al. Phase II randomized trial comparing sequential first-line everolimus and second-line sunitinib versus first-line sunitinib and second-line everolimus in patients with metastatic renal cell carcinoma. J Clin Oncol. 2014;32(5):2765–2772. doi:10.1200/JCO.2013.54.6911.; Choueiri T.K., Pal S.K. The treatment of advanced non-clear cell renal carcinoma. UpToDate. Available at: https://www.uptodate.com/contents/thetreatment-of-advanced-non-clear-cell-renal-carcinoma.; Bex A., Mulders P., Jewett M., Wagstaff J., van Thienen J.V., Blank C.U. et al. Comparison of immediate vs deferred cytoreductive nephrectomy in patients with synchronous metastatic renal cell carcinoma receiving sunitinib: the SURTIME randomized clinical trial. JAMA Oncol. 2019;5(2):164– 170. doi:10.1001/jamaoncol.2018.5543.; Woldu S.L., Matulay J.T., Clinton T.N., Singla N., Freifeld Y., Sanli O. et al. Incidence and outcomes of delayed targeted therapy after cytoreductive nephrectomy for metastatic renal-cell carcinoma: a nationwide cancer registry study. Clin Genitourin Cancer. 2018;16(6):e1221–35. doi:10.1016/j.clgc.2018.08.001.; Méjean A., Ravaud A., Thezenas S., Colas S., Beauval J.-B., Bensalah K. et al. Sunitinib alone or after nephrectomy in metastatic renal-cell carcinoma. N Engl J Med. 2018;379(5):417–427. doi:10.1056/NEJMoa1803675.; Choueiri T.K., Xie W., Kollmannsberger C., North S., Knox J.J., Lampard J.G. et al. The impact of cytoreductive nephrectomy on survival of patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor targeted therapy. J Urol. 2011;185(1):60–66. doi:10.1016/j.juro.2010.09.012.; Heng D.Y., Choueiri T.K., Rini B.I., Lee J., Yuasa T., Pal S.K. et al. Outcomes of patients with metastatic renal cell carcinoma that do not meet eligibility criteria for clinical trials. Ann Oncol. 2014;25(1):149–154. doi:10.1093/annonc/mdt492.; Motzer R.J., Hutson T.E., Cella D., Reeves J., Hawkins R., Guo J. et al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med. 2013;369:722–731. doi:10.1056/NEJMoa1303989.; Motzer R.J., Hutson T.E., McCann L., Choueiri T.K. Overall survival in renalcell carcinoma with pazopanib versus sunitinib. N Engl J Med. 2014;370:1769–1770. doi:10.1056/NEJMc1400731.; Motzer R.J., Bander N.H., Nanus D.M. Renal-cell carcinoma. New Eng J Med. 1996;335:865–875. doi:10.1056/NEJM199609193351207.; Moran M., Nickens D., Adcock K., Bennetts M., Desscan A., Charnley N., Fife K. Sunitinib for Metastatic Renal Cell Carcinoma: A Systematic Review and Meta-Analysis of Real-World and Clinical Trials Data. Target Oncol. 2019;14(4):405–416. doi:10.1007/s11523-019-00653-5.

Availability: https://www.med-sovet.pro/jour/article/view/5717
https://doi.org/10.21518/2079-701X-2020-9-136-145

Efficacy of incomplete metastasectomy in combination with targeted therapy in metastatic kidney cancer patients ; Оценка эффективности хирургического удаления метастазов в комбинации с таргетной терапией у больных метастатическим раком почки

Authors: P. S. Borisov, R. V. Orlova, M. I. Shkolnik, P. A. Karlov, E. E. Topuzov, П. С. Борисов, Р. В. Орлова, М. И. Школьник, П. А. Карлов, Э. Э. Топузов

Source: Cancer Urology; Том 15, № 4 (2019); 65-72 ; Онкоурология; Том 15, № 4 (2019); 65-72 ; 1996-1812 ; 1726-9776 ; 10.17650/1726-9776-2019-15-4

Subject Terms: метастатический почечно-клеточный рак, systemic therapy, metastatic renal cell carcinoma, системная терапия

File Description: application/pdf

Relation: https://oncourology.abvpress.ru/oncur/article/view/1014/896; Алексеев Б.Я., Калпинский A.C. Применение таргетных препаратов в лечении метастатического рака почки: последовательное назначение или комбинация. Онкоурология 2010;(4):16–23.; Ljungberg B., Bensalah K., Bex A. et al. Guidelines on renal cell carcinoma. EAU 2015. 30 p.; Psutka S.P., Chang S.L., Cahn D. et al. Reassessing the role of cytoreductive nephrectomy for metastatic renal cell carcinoma in 2019. Am Soc Clin Oncol Educ Book 2019;39:276–83. DOI:10.1200/EDBK_237453.; De Brujin R.E., Mulders P., Jewett M.A. et al. Surgical safety of cytoreductive nephrectomy following sunitinib: results from the multicentre, randomised controlled trial of immediate versus deferred nephrectomy (SURTIME). Eur Urol 2019;76(4):437–40. DOI:10.1016/j.eururo.2019.06.006.; Alt A.L., Boorjian S.A., Lohse C.M. et al. Survival after complete surgical resection of multiple metastases from renal cell carcinoma. Cancer 2011;117(13):2873–82. DOI:10.1002/cncr.25836.; Давыдов М.И., Матвеев В.Б., Полоцкий Б.Е. и др. Хирургическое лечение метастазов рака почки в легких. Российский онкологический журнал 2003;4:15–8.; You D., Lee C., Jeong I.G. et al. Impact of metastasectomy on prognosis in patients treated with targeted therapy for metastatic renal cell carcinoma. J Cancer Res Clin Oncol 2016;142(11):2331–8. DOI:10.1007/s00432-016-2217-1.; Ljungberg B., Albiges L., Bensalah K. et al. Guidelines on renal cell carcinoma. EAU 2018. Pp. 34–40.; https://oncourology.abvpress.ru/oncur/article/view/1014

Availability: https://oncourology.abvpress.ru/oncur/article/view/1014
https://doi.org/10.17650/1726-9776-2019-15-4-65-72

CURRENTLY AVAILABLE TREATMENT OPTIONS FOR METASTATIC RENAL CELL CARCINOMA ; СОВРЕМЕННЫЕ ВОЗМОЖНОСТИ ЛЕЧЕНИЯ МЕТАСТАТИЧЕСКОГО ПОЧЕЧНО-КЛЕТОЧНОГО РАКА

Authors: B. Ya. Alekseev, A. D. Kaprin, G. P. Kolesnikov, A. A. Mukhomed’yarova, E. I. Konopleva, A. S. Kalpinskiy, Б. Я. Алексеев, А. Д. Каприн, Г. П. Колесников, А. А. Мухомедьярова, Е. И. Коноплева, А. С. Калпинский

Contributors: Eisai Co., Ltd., Компания «Эйсай»

Source: Cancer Urology; Том 14, № 3 (2018); 25-36 ; Онкоурология; Том 14, № 3 (2018); 25-36 ; 1996-1812 ; 1726-9776 ; 10.17650/1726-9776-2018-14-3

Subject Terms: ингибитор тирозинкиназ, lenvatinib, metastatic renal cell carcinoma, targeted therapy, tyrosine kinase inhibitor, ленватиниб, метастатический почечно-клеточный рак, таргетная терапия

File Description: application/pdf

Relation: https://oncourology.abvpress.ru/oncur/article/view/879/782; International Agency for Research on Cancer. The GLOBOCAN project: cancer incidence and mortality worldwide in 2012. Available at: http://globocan.iarc.fr/Pages/fact_sheets_population.aspx.; Злокачественные новообразования в России в 2014 году (заболеваемость и смертность). Под ред. А.Д. Каприна, В.В. Старинского, Г.В. Петровой. М.: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2016. 250 с.; Ljungberg B., Albiges L., Bensalah K. et al. EAU Guidelines on renal cell carcinoma. Available at: http://uroweb.org/guideline/renal-cell-carcinoma/.; National Comprehensive Cancer Network, Inc. The NCCN Clinical Practice Guidelines in Oncology for Kidney Cancer. V.4.2018. Available at: https://www.nccn.org/professionals/physician_gls/pdf/kidney.pdf April 23, 2018.; Escudier B., Porta C., Schmidinger M. et al. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2016;27(suppl 5): 58–68. DOI:10.1093/annonc/mdw328. PMID: 27664262.; Клинические рекомендации по лечению рака паренхимы почки у взрослых Министерства здравоохранения Российской Федерации, версия 2017 г. Доступно по: http://cr.rosminzdrav.ru/#!/schema/87.; Motzer R.J., Hutson T.E., Tomczak P. et al. Sunitinib versus interferon alfa in metastatic renal cell carcinoma. N Engl J Med 2007;356(2):115–24. DOI:10.1056/NEJ-Moa065044. PMID: 17215529.; Sternberg C.N., Davis I.D., Mardiak J. et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 2010;28(6):1061–8. DOI:10.1200/JCO.2009.23.9764. PMID: 20100962.; Escudier B., Pluzanska A., Koralewski P. et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 2007;370(9605):2103–11. DOI:10.1016/S0140-6736(07)61904-7. PMID: 18156031.; Rini B.I., Halabi S., Rosenberg J.E. at al. Phase III trial bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J Clin Oncol 2010;28(13):2137–43. DOI:10.1200/JCO.2009.26.5561. PMID: 20368558.; Motzer R.J., Hutson T.E., Tomczak P. et al. Overall survival and updated results for sunitinib compared with interferon-alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 2009;27(22):3584–90. DOI:10.1200/JCO.2008.20.1293. PMID: 19487381.; Escudier B., Bellmunt J., Negrier S. et al. Phase III trial bevacizumab plus interferon alfa in patients with metastatic renal cell carcinoma (AVOREN): final results of overall survival. J Clin Oncol 2010;28(13):2144–50. DOI:10.1200/JCO.2009.26.7849. PMID: 20368553.; Sternberg C.N., Hawkins R.E., Wagstaff J. et al. A randomized, double-blind, phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: final overall survival results and safety update. Eur J Cancer 2013;49(6):1287–96. DOI:10.1016/j.ejca.2012.12.010. PMID: 23321547.; Hudes G., Carducci M., Tomczak P. et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007;356:2271–81.; Negrier S. Temsirolimus in metastatic renal cell carcinoma. Ann Onc 2008;19(8): 1369–70.; Motzer R.J., Escudier B., Oudard S. et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008;372(9637):449–56. DOI:10.1016/S0140-6736(08)61039-9. PMID: 18653228.; Rini B.I., Escudier B., Tomczak P. et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet 2011;378(9807):1931–9. DOI:10.1016/S0140-6736(11)61613-9. PMID: 22056247.; Motzer R.J., Escudier B., McDermott D.F. et al. Nivolumab versus Everolimus in advanced renal-cell carcinoma. N Engl J Med 2015;373(19):1803–13. DOI:10.1056/NEJ-Moa1510665. PMID: 26406148.; Choueiri T.K., Escudier B., Powles T. et al. Cabozantinib versus Everolimus in advanced renal-cell carcinoma. N Engl J Med 2015;373(19):1814–23. DOI:10.1056/NEJ-Moa1510016. PMID: 26406150.; Инструкция по применению лекарственного препарата для медицинского применения Ленвима. РУ № ЛП 003398. Дата регистрации 29.12.2015 (с изменениями от 06.12.2016).; Motzer R.J., Hutson T.E., Glen H. et al. Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial. Lancet Oncol 2015;16(15):1473–82. DOI:10.1016/S1470-2045(15)00290-9. PMID: 26482279.; Motzer R.J., Hutson T.E., Ren M. et al. Independent assessment of lenvatinib plus everolimus in patients with metastatic renal cell carcinoma. Lancet Oncol 2016;17(1):e4–5. DOI:10.1016/S1470-2045(15)00543-4. PMID: 26758760.; Grande E., Martínez-Sáez O., Gajate-Borau P., Alonso-Gordoa T. Translating new data to the daily practice in second line treatment of renal cell carcinoma: The role of tumor growth rate. World J Clin Oncol 2017;8(2):100–5. DOI:10.5306/wjco.v8. i2.100. PMID: 28439491.; https://oncourology.abvpress.ru/oncur/article/view/879

Availability: https://oncourology.abvpress.ru/oncur/article/view/879
https://doi.org/10.17650/1726-9776-2018-14-3-25-36

Potential biomarkers for nivolumab therapy of metastatic renal cell carcinoma ; Потенциальные биомаркеры эффективности терапии ниволумабом при метастатическом почечно-клеточном раке

Authors: M. S. Sayapina, N. A. Savyolov, N. V. Lyubimova, Yu. S. Timofeev, D. A. Nosov, М. С. Саяпина, Н. А. Савёлов, Н. В. Любимова, Ю. С. Тимофеев, Д. А. Носов

Source: Cancer Urology; Том 14, № 1 (2018); 16-27 ; Онкоурология; Том 14, № 1 (2018); 16-27 ; 1996-1812 ; 1726-9776 ; 10.17650/1726-9776-2018-14-1

Subject Terms: FOXP3, metastatic renal cell carcinoma, TGF-β1, IL-17A, sPD-1, PD-L1, метастатический почечно-клеточный рак

File Description: application/pdf

Relation: https://oncourology.abvpress.ru/oncur/article/view/699/735; Motzer R.J., Escudier B., McDermott D.F. et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med 2015;373(19):1803–13. DOI:10.1056/NEJMoa1510665. PMID: 26406148.; Thompson R.H., Dong H., Kwon E.D. Implications of B7-H1 expression in clear cell carcinoma of the kidney for prognostication and therapy. Clin Cancer Res 2007;13(2 Pt 2):709–15. DOI:10.1158/1078-0432.CCR-06-1868. PMID: 17255298.; Choueiri T.K., Fishman M.N., Escudier B.J. et al. Immunomodulatory activity of nivolumab in previously treated and untreated metastatic renal cell carcinoma (mRCC): biomarker-based results from a randomized clinical trial. J Clin Oncol 2014;32(suppl):5012. DOI:10.1200/jco.2014.32.15_suppl.5012.; Choueiri T.K., Fishman M.N., Escudier B. et al. Immunomodulatory activity of nivolumab in metastatic renal cell carcinoma (mRCC): association of biomarkers with clinical outcomes. J Clin Oncol 2015;33(suppl):4500. DOI:10.1200/jco.2015.33.15_suppl.4500.; Choueiri T.K., Figueroa D.J., Fay A.P. et al. Correlation of PD-L1 tumor expression and treatment outcomes in patients with renal cell carcinoma receiving sunitinib or pazopanib: results from COMPARZ, a randomized controlled trial. Clin Cancer Res 2015;21(5):1071–7. DOI:10.1158/1078-0432.CCR-14-1993. PMID: 25538263.; Li Z., Dong P., Ren M. et al. PD-L1 expression is associated with tumor FOXP3+ regulatory T-cell infiltration of breast cancer and poor prognosis of patient. J Cancer 2016;7(7):784–93. DOI:10.7150/jca.14549. PMID: 27162536.; Hou J., Yu Z., Xiang R. et al. Correlation between infiltration of FOXP3+ regulatory T-cells and expression of B7-H1 in the tumor tissues of gastric cancer. Exp Mol Pathol 2014;96(3):284–91. DOI:10.1016/j.yexmp.2014.03.005. PMID: 24657498.; Geng Y., Wang H., Lu C. et al. Expression of costimulatory molecules B7-H1, B7H4 and FOXP3+-T-regs in gastric cancer and its clinical significance. Int J Clin Oncol 2015;20(2):273–81. DOI:10.1007/s10147-014-0701-7. PMID: 24804867.; Powderly J.D., Koeppen H., Hodi F.S. et al. Biomarkers and associations with the clinical activity of PD-L1 blockade in a MPDL3280A study. J Clin Oncol 2013;31(suppl):3001. DOI:10.1200/jco.2013.31.15_suppl.3001.; Rossille D., Gressier M., Damotte D. et al. High level of soluble programmed cell death ligand 1 in blood impacts overall survival in aggressive diffuse large B-cell lymphoma: results from a French multicenter clinical trial. Leukemia 2014;28(12):2367–75. DOI:10.1038/leu.2014.137. PMID: 24732592.; Song M.Y., Park S.H., Nam H.J. et al. Enhancement of vaccine-induced primary and memory CD8+ T-cell responses by soluble PD-1. J Immunother 2011;34(3):297–306. DOI:10.1097/CJI.0b013e318210ed0e. PMID: 21389868.; Kuipers H., Muskens F., Willart M. et al. Contribution of the PD-1 ligands/PD-1 signaling pathway to dendritic cell-mediated CD4+ T-cell activation. Eur J Immunol 2006;36(9):2472–82. DOI:10.1002/eji.200635978. PMID: 16917960.; Peliçari K.O., Postal M., Sinicato N.A. et al. Serum interleukin-17 levels are associated with nephritis in childhood-onset systemic lupus erythematosus. Clinics (Sao Paulo) 2015;70(5):313–7. DOI:10.6061/clinics/2015(05)01. PMID: 26039945.; Waite J.C., Skokos D. Th17 response and inflammatory autoimmune diseases. Int J Inflam 2012;2012:819467. DOI:10.1155/2012/819467. PMID: 22229105.; Motzer R.J., Rini B.I., McDermott D.F. et al. Nivolumab for metastatic renal cell carcinoma: results of a randomized phase II trial. J Clin Oncol 2015;33(13):1430–7. DOI:10.1200/JCO.2014.59.0703. PMID: 25452452.; Rini B.I., McDermott D.F., Hammers H. et al. Society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of renal cell carcinoma. J Immunother Cancer 2016;4:81. DOI:10.1186/s40425-016-0180-7. PMID: 27891227.; https://oncourology.abvpress.ru/oncur/article/view/699

Availability: https://oncourology.abvpress.ru/oncur/article/view/699
https://doi.org/10.17650/1726-9776-2018-14-1-16-27

Consecutive targeted therapy in patients with metastatic kidney cancer

Authors: А. S. Kalpinskiy, A. D. Kaprin, A. A. Kostin, K. M. Nyushko

Source: Медицинский совет, Vol 0, Iss 8, Pp 66-73 (2015)

Subject Terms: метастатический почечно-клеточный рак, таргетная терапия, ингибиторы ангиогенеза, акситиниб, metastatic renal cell carcinoma, targeted therapy, angiogenesis inhibitors, axitinib, Medicine

File Description: electronic resource

Relation: https://www.med-sovet.pro/jour/article/view/231; https://doaj.org/toc/2079-701X; https://doaj.org/toc/2658-5790

Access URL: https://doaj.org/article/4b9811c70eed4caaaf9679d70aaea834

Possibilities of using alternative schemes of sunitinib therapy in patients with metastatic renal cell carcinoma ; Возможности применения альтернативных схем терапии сунитинибом у пациентов с метастатическим почечно-клеточным раком

Authors: A. V. Byakhov, A. A. Khisamov, А. В. Бяхов, А. А. Хисамов

Source: Malignant tumours; № 2 (2017); 90-93 ; Злокачественные опухоли; № 2 (2017); 90-93 ; 2587-6813 ; 2224-5057

Subject Terms: таргетная терапия, metastatic renal cell carcinoma, targeted therapy, метастатический почечно-клеточный рак

File Description: application/pdf

Relation: https://www.malignanttumors.org/jour/article/view/348/315; Hsieh J. J., Purdue M.P., Signoretti S., Swanton C., Albiges L., Schmidinger M., Heng D.Y., Larkin J., Ficarra V. Renal cell carcinoma., Nat.Rev. Dis. Primers., 2017, Vol. 3, pp. 17009. doi:10.1038/nrdp. 2017.9.; Ferlay J. et al. GLOBOCAN 2012 v1. 0, Cancer incidence and mortality worldwide: IARC Cancer Base No. 1, 2013, GLOBOCAN http://globocan.iarc.fr (accessed on 4 Aug 2016).; Torre L.A. et al. Global cancer statistics, 2012, CA Cancer J. Clin., 2015, Vol. 65, pp. 87–108.; Global Burden of Disease Cancer Collaboration et al. The Global Burden of Cancer 2013, JAMA Oncol., 2015, Vol. 1, pp. 505–527.; Каприн А.Д., Старинский В.В., Петрова Г.В., Злокачественные новообразования в России в 2015 году (заболеваемость и смертность). Москва, 2017. 250 с. [Kaprin A.D., Starinskiy V.V., Petrova G.V. Malignant neoplasms in Russia in 2015 (morbidity and mortality), Moscow, 2017, 250 p. (In Russ.)].; Motzer R. J., Hutson T. E., McCann L., Deen K., Choueiri T.K. Overall survival in renal-cell carcinoma with pazopanib versus sunitinib, N. Engl. J. Med., 2014, Vol. 370, pp. 1769–1770.; Schmid T.A., Gore M. E. Sunitinib in the treatment of metastatic renal cell carcinoma, Ther.Adv. Urol., 2016, Vol. 8, No. 6, pp. 348–371. Epub 2016 Aug 23.; Bracarda S., Negrier S., Casper J., Porta C., Schmidinger M., Larkin J., Gross Goupil M., Escudier B. How clinical practice is changing the rules: the sunitinib 2/1 schedule in metastatic renal cell carcinoma, Expert. Rev. Anticancer Ther., 2017, Vol. 17, No. 3, pp. 227–233. doi:10.1080/14737140.2017.1276830. Epub 2017 Jan 3. Review.; Faivre S., Delbaldo C., Vera K., Robert C., Lozahic S., Lassau N., Bello C., Deprimo S., Brega N., Massimini G., Armand J.P., Scigalla P., Raymond E. J. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosinekinase inhibitor, in patients with cancer, Clin. Oncol., 2006, Vol. 24, No. 1, pp. 25–35. Epub 2005 Nov 28.; Motzer R. J., Hutson T. E., Tomczak P., Michaelson M.D., Bukowski R.M., Oudard S., Negrier S., Szczylik C., Pili R., Bjarnason G.A., Garcia-del-Muro X., Sosman J.A., Solska E., Wilding G., Thompson J.A., Kim S. T., Chen I., Huang X., Figlin R.A. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma, J. Clin. Oncol., 2009, Vol. 27, No. 22, pp. 3584–90. doi:10.1200/JCO. 2008.20.1293. Epub 2009 Jun 1.; Motzer R. J., Hutson T. E., Tomczak P., Michaelson M.D., Bukowski R.M., Rixe O., Oudard S., Negrier S., Szczylik C., Kim S. T., Chen I., Bycott P.W., Baum C.M., Figlin R.A. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma, N. Engl. J. Med., 2007, Vol. 356, No. 2, pp. 115–24.; Motzer R.J., Hutson T.E., Cella D. et al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma, N. Engl. J. Med., 2013, Vol. 369, No. 8, pp. 722–31. doi:10.1056 / NEJMoa1303989.; Houk B. E., Bello C. L., Poland B., Rosen L.S., Demetri G.D., Motzer R. J. Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis. Cancer Chemother. Pharmacol., 2010, Vol. 66, No. 2, pp. 357–71. doi:10.1007/s00280-009-1170-y. Epub 2009 Dec 5.; Britten C.D., Kabbinavar F., Hecht J.R. et al. A phase I and pharmacokinetic study of sunitinib administered daily for 2 weeks, followed by a 1-week off period, Cancer Chemother, Pharmacol., 2008, Vol. 61, pp. 515–524.; Atkinson B. J., Kalra S., Wang X. et al. Clinical outcomes for patients with metastatic renal cell carcinoma treated with alternative sunitinib schedules, J. Urol., 2014, Vol. 191, pp. 611–618.; Bjarnason G.A., Khalil B., Hudson J.M. et al. Outcomes in patients with metastatic renal cell cancer treated with individualized sunitinib therapy: correlation with dynamic microbubble ultrasound data and review of the literature, Urol. Oncol., 2014, Vol. 32, pp. 480–487.; Bracarda S., Iacovelli R., Boni L. et al. Sunitinib administered on 2/1 schedule in patients with metastatic renal cell carcinoma: the RAINBOW analysis, Ann. Oncol., 2015, Vol. 26, pp. 2107–2113.; Kondo T., Takagi T., Kobayashi H. et al. Superior tolerability of altered dosing schedule of sunitinib with 2-weeks-on and 1-weekoff in patients with metastatic renal cell carcinoma – comparison to standard dosing schedule of 4-weeks-on and 2-weeks-off, Jpn. J. Clin. Oncol., 2014, Vol. 44, pp. 270–277.; Najjar Y.G., Mittal K., Elson P. et al. A 2 weeks on and 1 week off schedule of sunitinib is associated with decreased toxicity in metastatic renal cell carcinoma, Eur. J. Cancer, 2014, Vol. 50, pp. 1084–1089.; Lee J.L., Kim M.K., Park I. et al. Randomized phase II trial of sunitinib four weeks on and two weeks off versus two weeks on and one week off in metastatic clear-cell type renal cell carcinoma: RESTORE trial, Ann. Oncol., 2015, Vol. 26, No. 11, pp. 2300–2305.; Neri B., Vannini A., Brugia M. et al. Biweekly sunitinib regimen reduces toxicity and retains efficacy in metastatic renal cell carcinoma: a single-center experience with 31 patients, Int. J. Urol., 2013, Vol. 20, pp. 478–483.; Yoo C., Kim J. E., Lee J. L. et al. The efficacy and safety of sunitinib in Korean patients with advanced renal cell carcinoma: high incidence of toxicity leads to frequent dose reduction, Jpn. J. Clin. Oncol., 2010, Vol. 40, pp. 980–985.; Population pharmacokinetic/pharmacodynamic modeling of sunitinib by dosing schedule in patients with advanced renal cell carcinoma or gastrointestinal stromal tumor, Clin. Pharmacokinet., 2016, Vol. 55, pp. 1251–1269.; https://www.malignanttumors.org/jour/article/view/348

Availability: https://www.malignanttumors.org/jour/article/view/348
https://doi.org/10.18027/2224-5057-2017-2-90-93

A new alternating regimen in metastatic renal cell carcinoma presented through a clinical case ; Новый альтернирующий режим при метастатическом почечно-клеточном раке на примере клинического случая

Authors: M. S. Sayapina, S. V. Shiryaev, A. S. Krylov, A. D. Ryzhkov, D. A. Titov, D. A. Nosov, М. С. Саяпина, С. В. Ширяев, А. С. Крылов, А. Д. Рыжков, Д. А. Титов, Д. А. Носов

Source: Cancer Urology; Том 12, № 4 (2016); 35-42 ; Онкоурология; Том 12, № 4 (2016); 35-42 ; 1996-1812 ; 1726-9776 ; 10.17650/1726-9776-2016-12-4

Subject Terms: метастатический почечно-клеточный рак, immunotherapy, targeted therapy, metastatic renal cell carcinoma, иммунотерапия, таргетная терапия

File Description: application/pdf

Relation: https://oncourology.abvpress.ru/oncur/article/view/585/604; Злокачественные новообразования в России в 2014 году (заболеваемость и смертность). Под ред. А.Д. Каприна, В.В. Старинского, Г.В. Петровой. М.: ФГБУ «Московский научно-исследовательский онкологический институт им. П.А. Герцена» – филиал ФГБУ «Национальный медицинский исследовательский радиологический центр» Минздрава России, 2016. 250 с. [Malignant tumors in Russia in 2014 (morbidity and fatality). Eds. by: А.D. Kaprin, V.V. Starinskiy, G.V. Petrova. Мoscow: FGBU “Moskovskiy nauchno-issledovatel’skiy onkologicheskiy institut im. P.A. Gertsena” – filial FGBU “Natsional’nyy meditsinskiy issledovatel’skiy radiologicheskiy tsentr” Minzdrava Rossii, 2016. 250 p. (In Russ.)].; Hutson T.E., Bukowski R.M., Cowey C.L. et al. Sequential use of targeted agents in the treatment of renal cell carcinoma. Crit Rev Oncol Hematol 2010;77(1):48–62. DOI:10.1016/j.critrevonc.2010.07.018. PMID: 20705477.; Vogelzang N.J., Samlowski W., Weissman A. Long-term response in primary renal cancer to sequential antiangiogenic therapy. J Clin Oncol 2009;27(26):e106–7. DOI:10.1200/JCO.2009.23.4021. PMID: 19667262.; Oudard S. More than 4 years of progression-free survival in a patient with metastatic renal cell carcinoma treated sequentially with sunitinib, everolimus, sorafenib, and temsirolimus. Anticancer Res 2010;30(12):5223–5. PMID: 21187517.; Bukowski R.M. Natural history and therapy of metastatic renal cell carcinoma: the role of interleukin-2. Cancer 1997;80(7):1198–220. PMID: 9317170.; Ott P.A., Adams S. Small-molecule protein kinase inhibitors and their effects on the immune system: implications for cancer treatment. Immunotherapy 2011;3(2): 213–27. DOI:10.2217/imt.10.99. PMID: 21322760.; Zheng Y., Collins S.L., Lutz M.A. et al. A role for mammalian target of rapamycin in regulating T-cell activation versus anergy. J Immunol 2007;178(4):2163–70. PMID: 17277121.; Finke J.H., Rini B., Ireland J. et al. Sunitinib reverses type-1 immune suppression and decreases T-regulatory cells in renal cell carcinoma patients. Clin Cancer Res 2008;14(20):6674–82. DOI:10.1158/1078-0432.CCR-07-5212. PMID: 18927310.; Носов Д.А. Метастатический рак почки: новые лекарственные возможности и рациональные лечебные подходы. Дис. … д-ра мед. наук. М., 2012. [Nosov D.A. Metastatic kidney cancer: new drug opportunities and rational therapeutic approaches. Thesis … of doctor of medical sciences. Moscow, 2012. (In Russ.)].; Ozao-Choy J., Ma G., Kao J. et al. The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies. Cancer Res 2009;69(6):2514–22. DOI:10.1158/0008-5472.CAN-08-4709. PMID: 19276342.; Adotevi O., Pere H., Ravel P. et al. A decrease of regulatory T-cells correlates with overall survival after sunitinib-based antiangiogenic therapy in metastaticrenal cancer patients. J Immunother 2010;33(9):991–8. DOI:10.1097/CJI.0b013e3181f4c208. PMID: 20948437.; van Cruijsen H., van der Veldt A.A., Vroling L. et al. Sunitinib-induced myeloid lineage redistribution in renal cell cancer patients: CD1c+ dendritic cell frequency predicts progression-free survival. Clin Cancer Res 2008;14(18):5884–92. DOI:10.1158/1078-0432.CCR-08-0656. PMID: 18794101.; Ko J.S., Zea A.H., Rini B.I. et al. Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients. Clin Cancer Res 2009;15(6):2148–57. DOI:10.1158/1078-0432.CCR-08-1332. PMID: 19276286.; Bex A., Jonasch E., Vyth-Dreese F. et al. Presurgical bevacizumab and sunitinib induced changes in primary clear cell renal tumor tissue. J Clin Oncol 2010;28(15).; Bex A., Etto T., Vyth-Dreese F. et al. Immunological heterogeneity of the RCC microenvironment: do targeted therapies influence immune response. Curr Oncol Rep 2012;14(3):230–9. DOI:10.1007/s11912-012-0229-9. PMID: 22362358.; Jonasch E., Hoang A., Sun M. et al. Sunitinib to upregulate IFNg-STAT1 signaling and to increase indoleamine 2,3-dioxygenase (IDO) expression in renal cell carcinoma (RCC). J Clin Oncol 2016;34.; Rabinovich G.A., Gabrilovich D., Sotomayor E.M. Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol 2007;25:267–96. DOI:10.1146/annurev.immunol.25.022106.141609. PMID: 17134371.; Hipp M.M., Hilf N., Walter S. et al. Sorafenib, but not sunitinib, affects function of dendritic cells and induction of primary immune responses. Blood 2008;111(12): 5610–20. DOI:10.1182/blood-2007-02-075945. PMID: 18310500.; Procaccini C., de Rosa V., Galgani M. et al. An oscillatory switch in mTOR kinase activity sets regulatory T-cell responsiveness. Immunity 2010;33(6):929–41. DOI:10.1016/j.immuni.2010.11.024. PMID: 21145759.; Wang Y., Camirand G., Lin Y. et al. Regulatory T-cells require mammalian target of rapamycin signaling to maintain both homeostasis and alloantigen-driven proliferation in lymphocyte-replete mice. J Immunol 2011;186(5):2809–18. DOI:10.4049/jimmunol.0903805. PMID: 21270412.; Vannema M., Dranoff G. Combining immunotherapy and targeted therapies in cancer treatment. Nat Rev Cancer 2012;12(4):237–51. DOI:10.1038/nrc3237. PMID: 22437869.; Hudes G., Carducci M., Tomczak P. et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007;356(22):2271–81. DOI:10.1056/NEJMoa066838. PMID: 17538086.; Motzer R.J., Hudes G., Wilding G. et al. Phase I trial of sunitinib malate plus interferonalpha for patients with metastatic renal cell carcinoma. Clin Genitourin Cancer 2009;7(1):28–33. DOI:10.3816/CGC.2009.n.005. PMID: 19213665.; Negrier S., Gravis G., Perol D. et al. Temsirolimus and bevacizumab, or sunitinib, or interferon alfa and bevacizumab for patients with advanced renal cell carcinoma (TORAVA): a randomised phase 2 trial. Lancet Oncol 2011;12(7):673–80. DOI:10.1016/S1470-2045(11)70124-3. PMID: 21664867.; Cirkel G.A., Hamberg P., Sleijfer S. et al. A randomized phase II study to compare the efficacy of upfront bi-monthly rotations between pazopanib (PAZ) and everolimus (EVE) versus sequential treatment of first-line PAZ and second-line EVE until progression in patients with metastatic clear cell renal cell cancer (ccRCC) (ROPETAR trial). J Clin Oncol 2016;34.; Rini B.I., Escudier B., Tomczak P. et al. Comparative eff ectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomized phase 3 trial. Lancet 2011;378(9807):1931–9. DOI:10.1016/S0140-6736(11)61613-9. PMID: 22056247.; Motzer R.J., Alyasova A., Ye D., et al. Phase II trial of second-line everolimus in patients with metastatic renal cell carcinoma (RECORD-4). Ann Oncol 2015;27(3):441–8. DOI:10.1093/annonc/mdv612. PMID: 26681676.; Escudier B., Eisen T., Stadler W.M. et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;356(2): 125–34. DOI:10.1056/NEJMoa060655. PMID: 17215530.; Rini B.I., Wood L.S., Elson P. et al. A phase II study of intermittent sunitinib (S) in previously untreated patients (pts) with metastatic renal cell carcinoma (mRCC). J Clin Oncol 2013;31.; Motzer R.J., Rini B.I., Bukowski R.M. et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA 2006;295(21)2516–24. DOI:10.1001/jama.295.21.2516. PMID: 16757724.; https://oncourology.abvpress.ru/oncur/article/view/585

Availability: https://oncourology.abvpress.ru/oncur/article/view/585
https://doi.org/10.17650/1726-9776-2016-12-4-35-42

Применение таргетной терапии и выбор оптимальной последовательности лечения в гетерогенной популяции больных метастатическим раком почки. Результаты ретроспективного исследования

Authors: БОРИСОВ П.С., ШКОЛЬНИК М.И., ОРЛОВА Р.В., КАРЛОВ П.А.

Subject Terms: METASTATIC RENAL CELL CANCER,TARGETED MEDICATIONS,PROGRESSION-FREE SURVIVAL,OVERALL SURVIVAL,МЕТАСТАТИЧЕСКИЙ ПОЧЕЧНО-КЛЕТОЧНЫЙ РАК,ТАРГЕТНЫЕ ПРЕПАРАТЫ,ВЫЖИВАЕМОСТЬ БЕЗ ПРОГРЕССИРОВАНИЯ,ОБЩАЯ ВЫЖИВАЕМОСТЬ

File Description: text/html

Availability: http://cyberleninka.ru/article/n/primenenie-targetnoy-terapii-i-vybor-optimalnoy-posledovatelnosti-lecheniya-v-geterogennoy-populyatsii-bolnyh-metastaticheskim-rakom
http://cyberleninka.ru/article_covers/16889082.png

Применение сунитиниба в реальной клинической практике у больных метастатическим раком почки

Authors: АЛЕКСЕЕВ Б.Я., НЮШКО К.М., КАЛПИНСКИЙ А.С.

Subject Terms: МЕТАСТАТИЧЕСКИЙ ПОЧЕЧНО-КЛЕТОЧНЫЙ РАК,ТАРГЕТНАЯ ТЕРАПИЯ,ИНГИБИТОРЫ ТИРОЗИНКИНАЗ,СУНИТИНИБ

File Description: text/html

Availability: http://cyberleninka.ru/article/n/primenenie-sunitiniba-v-realnoy-klinicheskoy-praktike-u-bolnyh-metastaticheskim-rakom-pochki
http://cyberleninka.ru/article_covers/16870114.png

Neoadjuvant targeted therapy in patients with renal cell carcinoma ; Неоадъювантная таргетная терапия у больных почечно-клеточным раком

Authors: B. Ya. Alekseev, K. M. Nyushko, A. S. Kalpinsky, Б. Я. Алексеев, К. М. Нюшко, А. С. Калпинский

Source: Cancer Urology; Том 11, № 2 (2015); 23-33 ; Онкоурология; Том 11, № 2 (2015); 23-33 ; 1996-1812 ; 1726-9776 ; 10.17650/1726-9776-2015-11-2

Subject Terms: неоадъювантная таргетная терапия, metastatic renal cell carcinoma, cytoreductive nephrectomy, radical nephrectomy, targeted therapy, sorafenib, sunitinib, bevacizumab, axitinib, pazopanib, neoadjuvant targeted therapy, метастатический почечно-клеточный рак, циторедуктивная нефрэктомия, радикальная нефрэктомия, таргетная терапия, сорафениб, сунитиниб, бевацизумаб, акситиниб, пазопаниб

File Description: application/pdf

Relation: https://oncourology.abvpress.ru/oncur/article/view/450/433; International Agency for Research on Cancer. The GLOBOCAN project: cancer incidence and mortality worldwide in 2012. Доступно по адресу: http://globocan.iarc.fr/; Злокачественные новообразования в России в 2013 году: заболеваемость и смертность. Под ред. А. Д. Каприна, В. В. Старинского, Г. В. Петровой. М., 2015. [Malignant neoplasms in Russia in 2013: morbidity and mortality. Ed. A. D. Caprin, V. V. Starinskiy, G. V. Petrova. Moscow, 2015. (In Russ.)].; Flanigan R.C., Yonover P.M. The role of radical nephrectomy in metastatic renal cell carcinoma. Semin Urol Oncol ;19(2):98–102.; Bex A., Powles T. Selecting patients for cytoreductive nephrectomy in advanced renal cell carcinoma: who and when. Expert Rev. Anticancer Ther 2012; 12(6):787–97.; Flanigan R. C., Salmon S. E., Blumenstein B. A. et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renalcell cancer. N Engl J Med 2001;345(23):1655–9.; Mickisch G. H., Garin A., Van Poppel H. et al. Radical nephrectomy plus interferonalfa- based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet 2001;358(9286):966–70.; Flanigan R. C., Mickisch G., Sylvester R. et al. Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. J Urol 2004;171:1071–6.; Motzer R. J., Bukowski R. M., Figlin R. A. et al. Prognostic nomogram for sunitinib in patients with metastatic renal cell carcinoma. Cancer 2008;113(7): 1552–8.; Wood C. G. Multimodal approaches in the management of locally advanced and metastatic renal cell carcinoma: combining surgery and systemic therapies to improve patient outcome. Clin Cancer Res 2001; 13(2 Pt 2):697–702.; Zini L., Capitanio U., Perrotte P. et al. Population-based assessment of survival after cytoreductive nephrectomy versus no surgery in patients with metastatic renal cell carcinoma. Urology 2009;73(2): 342–6.; Choueiri T. K., Xie W., Kollmannsberger C. et al. The impact of cytoreductive nephrectomy on survival of patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor targeted therapy. J Urol 2011;185(1):60–6.; Warren M., Venner P. M., North S. et al. A population-based study examining the effect of tyrosine kinase inhibitors on survival in metastatic renal cell carcinoma in Alberta and the role of nephrectomy prior to treatment. Can Urol Assoc J 2001;3(4):281–9.; Aben K. K., Heskamp S., Janssen-Heijnen M. L. et al. Better survival in patients with metastasised kidney cancer after nephrectomy: a population-based study in the Netherlands. Eur J Cancer 2011;47(13):2023–32.; Kutikov A., Uzzo R. G., Caraway A. et al. Use of systemic therapy and factors affecting survival for patients undergoing cytoreductive nephrectomy. BJU Int 2010;106(2):218–23.; Abdollah F., Sun M., Thuret R. et al. Mortality and morbidity after cytoreductive nephrectomy for metastatic renal cell carcinoma: a population-based study. Ann Surg Oncol 2011;18(10):2988–96.; Mizutani Y. Recent advances in molecular targeted therapy for metastatic renal cell carcinoma. Int J Urol 2009;16:444–8.; Sonpavde G., Sternberg C. N. Neoadjuvant systemic therapy for urological malignancies. BJU Int 2010;106:6–22.; Shuch B., Riggs S. B., LaRochelle J.C. et al. Neoadjuvant targeted therapy and advanced kidney cancer: observations and implications for a new treatment paradigm. BJU Int 2008;102:692–6.; Schrader A. J., Steffens S., Schnoeller T. J. et al. Neoadjuvant therapy of renal cell carcinoma: A novel treatment option in the era of targeted therapy? Int J Urol 2012;19:903–7.; Silberstein J. L., Millard F., Mehrazin R. et al. Feasibility and efficacy of neoadjuvant sunitinib before nephron-sparing surgery. BJU Int 2010;106:1270–6.; Hellenthal N. J., Underwood W., Penetrante R. et al. Prospective clinical trial of preoperative sunitinib in patients with renal cell carcinoma. J Urol 2010;184:859–64.; Bex A., van der Veldt A. A., Blank C. et al. Neoadjuvant sunitinib for surgically complex advanced renal cell cancer of doubtful resectability: initial experience with downsizing to reconsider cytoreductive surgery. World J Urol 2009;27:533–9.; Powles T., Kayani I., Blank C. et al. The safety and efficacy of sunitinib before planned nephrectomy in metastatic clear cell renal cancer. Ann Oncol 2011;22: 1041–7.; Margulis V., Matin S. F., Tannir N. et al. Surgical morbidity associated with administration of targeted molecular therapies before cytoreductive nephrectomy or resection of locally recurrent renal cell carcinoma. J Urol 2008;180:94–8.; Chapin B. F., Delacroix S. E.Jr, Culp S. H. et al. Safety of presurgical targeted therapy in the setting of metastatic renal cell carcinoma. Eur Urol 2011;60:964–71.; Wood C. G., Margulis V. Neoadjuvant (presurgical) therapy for renal cell carcinoma: a new treatment paradigm for locally advanced and metastatic disease. Cancer 2009;115:2355–60.; Abel E. J., Culp S. H., Tannir N. M. et al. Primary tumor response to targeted agents in patients with metastatic renal cell carcinoma. Eur Urol 2011;59:10–5.; Harshman L. C., Yu R. J., Allen G. I. et al. Surgical outcomes and complications associated with presurgical tyrosine kinase inhibition for advanced renal cell carcinoma (RCC). Urol Oncol 2011.; Karakiewicz P. I., Suardi N., Jeldres C. et al. Neoadjuvant sutent induction therapy may effectively down-stage renal cell carcinoma atrial thrombi. Eur Urol 2008;53:845–8.; Di Silverio F., Sciarra A., Parente U. et al. Neoadjuvant therapy with sorafenib in advanced renal cell carcinoma with vena cava extension submitted to radical nephrectomy. Urol. Int. 2008;80: 451–3.; Kondo T., Hashimoto Y., Kobayashi H. et al. Presurgical targeted therapy with tyrosine kinase inhibitors for advanced renal cell carcinoma: clinical results and histopathological therapeutic effects. Jpn J Clin Oncol 2010;40:1173–9.; Harshman L. C., Srinivas S., Kamaya A., Chung B. I. Laparoscopic radical nephrectomy after shrinkage of a caval tumor thrombus with sunitinib. Nat Rev Urol 2009;6:338–43.; Robert G., Gabbay G., Bram R. et al. Case study of the month. Complete histologic remission after sunitinib neoadjuvant therapy in T3b renal cell carcinoma. Eur Urol 2009;55:1477–80.; Bex A., van der Veldt A. A., Blank C. et al. Progression of a caval vein thrombus in two patients with primary renal cell carcinoma ыon pretreatment with sunitinib. Acta Oncol 2010;49:520–3.; Cost N. G., Delacroix S. E.Jr, Sleeper J. P. et al. The impact of targeted molecular therapies on the level of renal cell carcinoma vena caval tumor thrombus. Eur Urol 2011;59:912–8.; Cowey C. L., Amin C., Pruthi R. S. et al. Neoadjuvant clinical trial with sorafenib for patients with stage II or higher renal cell carcinoma. J Clin Oncol 2010;28:1502–7.; Thomas A. A., Rini B. I., Stephenson A. J. et al. Surgical resection of renal cell carcinoma after targeted therapy. J Urol 2009;182(3):881–6.; Amin C., Wallen E., Pruthi R. S. et al. Preoperative tyrosine kinase inhibition as an adjunct to debulking nephrectomy. Urology 2008;72(4):864–8.; Jonasch E., Wood C. G., Matin S. F. et al. Phase II presurgical feasibility study of bevacizumab in untreated patients with metastatic renal cell carcinoma. J Clin Oncol 2009;27:4076–81.; Powles T., Sarwar N., Stockdale A. et al. Pazopanib prior to planned nephrectomy in metastatic clear cell renal cancer: A clinical and biomarker study. J Clin Oncol 2013;31 (suppl; abstr 4508).; Rini B. I., Plimack E. R., Takagi T. et al. A phase ii study of pazopanib in patients with localized renal cell carcinoma to optimize preservation of renal parenchyma. J Urol 2015 Mar 23. pii: S0022–5347(15) 03398–4.; Alvarez A. L., Plimack E. R., Dreicer R. et al. A phase II study of pazopanib in patients with localized renal cell carcinoma to enable partial nephrectomy. J Clin Oncol 2014;32:5 (suppl; abstr 4522).; Karam J. A., Devine C. E., Urbauer D. L. et al. Phase II trial of neoadjuvant axitinib in patients with locally advanced nonmetastatic clear cell renal cell carcinoma. J Clin Oncol (Meeting Abstracts) 2014;32:441.; Lane B. R., Derweesh I. H., Kim H. L. et al. Presurgical sunitinib reduces tumor size and may facilitate partial nephrectomy in patients with renal cell carcinoma. Urol Oncol 2015;33(3):112. e15–21.; https://oncourology.abvpress.ru/oncur/article/view/450

Availability: https://oncourology.abvpress.ru/oncur/article/view/450
https://doi.org/10.17650/1726-9776-2015-11-2-23-33

Sorafenib is the first targeted agent to treat metastatic kidney cancer ; Сорафениб – первый таргетный агент для лечения метастатического рака почки

Authors: V. B. Matveev, V. A. Chernyaev, В. Б. Матвеев, В. А. Черняев

Source: Cancer Urology; Том 11, № 1 (2015); 73-78 ; Онкоурология; Том 11, № 1 (2015); 73-78 ; 1996-1812 ; 1726-9776 ; 10.17650/1726-9776-2015-11-1

Subject Terms: выживаемость, sunitinib, pazopanib, everolimus, axitinib, bevacizumab, kidney cancer, metastatic renal cell carcinoma, targeted therapy, survival, сунитиниб, пазопаниб, эверолимус, акситиниб, бевацизумаб, рак почки, метастатический почечно- клеточный рак, таргетная терапия

File Description: application/pdf

Relation: https://oncourology.abvpress.ru/oncur/article/view/421/431; http://www.fda.gov/NewsEvents/ Newsroom/PressAnnouncements/2005/ ucm108538.htm; Escudier B., Eisen T., Stadler W.M. et al. Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol 2009;27:3312–8.; Motzer R.J., Nosov D., Eisen T. et al. Tivozanib versus sorafenib as initial targeted therapy for patients with metastatic renal cell carcinoma: results from a phase III trial. J Clin Oncol 2013;31:3791–9.; Motzer R.J., Porta C., Vogelzang N.J. et al. Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial. Lancet Oncol 2014;15:286–96.; Yuan J.L., Wang F.L., Yi X.M. et al. More than 10 years survival with sequential therapy in a patient with advanced renal cell carcinoma: a case report. Braz J Med Biol Res 2015;48(1):34–8.; Hutson T.E., Escudier B., Esteban E. et al. Randomized Phase III Trial of Temsirolimus Versus Sorafenib As Second-Line Therapy After Sunitinib in Patients With Metastatic Renal Cell Carcinoma. J Clin Oncol 32: 760–7.; Escudier B., Porta C., Bono P. et al. Randomized, controlled, double-blind, cross- over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES Study. J Clin Oncol 2014;32(14):1412–8.; Motzer R.J., Hutson T.E., Tomczak P. et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 2009;27(22):3584–90.; Motzer R.J., Hutson T.E, Cella D. et al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med 2013;369(8):722–31.; Sternberg C.N., Hawkins R.E., Wagstaff J. et al. A randomised, double-lind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: final overall survival results and safety update. Eur J Cancer 2013;49(6): 1287–96.; Michel M.S., Vervenne W., de Santis M. et al. SWITCH: A randomized sequential open-label study to evaluate efficacy and safety of sorafenib (SO)/sunitinib (SU) versus SU/SO in the treatment of metastatic renal cell cancer (mRCC). J Clin Oncol 2014;32 (suppl 4; abstr 393).; https://oncourology.abvpress.ru/oncur/article/view/421

Availability: https://oncourology.abvpress.ru/oncur/article/view/421
https://doi.org/10.17650/1726-9776-2015-1-73-78

Оценка эффективности комплексного паллиативного лечения у больных метастатическим светлоклеточным почечно-клеточным раком

Authors: БОРИСОВ П.С., ОРЛОВА Р.В., ШКОЛЬНИК М.И., КАРЛОВ П.А.

Subject Terms: МЕТАСТАТИЧЕСКИЙ ПОЧЕЧНО-КЛЕТОЧНЫЙ РАК,НЕПОЛНАЯ МЕТАСТАЗЭКТОМИЯ,НЕПОЛНАЯ ЦИТОРЕДУКЦИЯ,ЦИТОРЕДУКТИВНОЕ ВМЕШАТЕЛЬСТВО,ПАЛЛИАТИВНОЕ ЛЕЧЕНИЕ МЕТАСТАТИЧЕСКОГО РАКА ПОЧКИ,КОМПЛЕКСНОЕ ЛЕЧЕНИЕ МЕТАСТАТИЧЕСКОГО РАКА ПОЧКИ,ТАРГЕТНАЯ ТЕРАПИЯ,ТЕРАПИЯ ЦИТОКИНАМИ,СОРАФЕНИБ,СУНИТИНИБ,ЭВЕРОЛИМУС,АКСИТИНИБ,ИНТЕРФЕРОН α

File Description: text/html

Availability: http://cyberleninka.ru/article/n/otsenka-effektivnosti-kompleksnogo-palliativnogo-lecheniya-u-bolnyh-metastaticheskim-svetlokletochnym-pochechno-kletochnym-rakom
http://cyberleninka.ru/article_covers/16870149.png

Неоадъювантная таргетная терапия у больных почечно-клеточным раком

Authors: АЛЕКСЕЕВ Б.Я., НЮШКО К.М., КАЛПИНСКИЙ А.С.

Subject Terms: ПОЧЕЧНО-КЛЕТОЧНЫЙ РАК,МЕТАСТАТИЧЕСКИЙ ПОЧЕЧНО-КЛЕТОЧНЫЙ РАК,ЦИТОРЕДУКТИВНАЯ НЕФРЭКТОМИЯ,РАДИКАЛЬНАЯ НЕФРЭКТОМИЯ,ТАРГЕТНАЯ ТЕРАПИЯ,СОРАФЕНИБ,СУНИТИНИБ,БЕВАЦИЗУМАБ,АКСИТИНИБ,ПАЗОПАНИБ,НЕОАДЪЮВАНТНАЯ ТАРГЕТНАЯ ТЕРАПИЯ

File Description: text/html

Availability: http://cyberleninka.ru/article/n/neoadyuvantnaya-targetnaya-terapiya-u-bolnyh-pochechno-kletochnym-rakom
http://cyberleninka.ru/article_covers/16870131.png

Применение таргетной терапии и выбор оптимальной последовательности лечения в гетерогенной популяции больных метастатическим раком почки. Результаты ретроспективного исследования

Source: Онкоурология.

Subject Terms: 03 medical and health sciences, 0302 clinical medicine, METASTATIC RENAL CELL CANCER,TARGETED MEDICATIONS,PROGRESSION-FREE SURVIVAL,OVERALL SURVIVAL,МЕТАСТАТИЧЕСКИЙ ПОЧЕЧНО-КЛЕТОЧНЫЙ РАК,ТАРГЕТНЫЕ ПРЕПАРАТЫ,ВЫЖИВАЕМОСТЬ БЕЗ ПРОГРЕССИРОВАНИЯ,ОБЩАЯ ВЫЖИВАЕМОСТЬ, 3. Good health

File Description: text/html

Access URL: http://cyberleninka.ru/article_covers/16889082.png
http://cyberleninka.ru/article/n/primenenie-targetnoy-terapii-i-vybor-optimalnoy-posledovatelnosti-lecheniya-v-geterogennoy-populyatsii-bolnyh-metastaticheskim-rakom

Применение сунитиниба в реальной клинической практике у больных метастатическим раком почки

Source: Онкоурология.

Subject Terms: 03 medical and health sciences, 0302 clinical medicine, МЕТАСТАТИЧЕСКИЙ ПОЧЕЧНО-КЛЕТОЧНЫЙ РАК,ТАРГЕТНАЯ ТЕРАПИЯ,ИНГИБИТОРЫ ТИРОЗИНКИНАЗ,СУНИТИНИБ, 3. Good health

File Description: text/html

Access URL: http://cyberleninka.ru/article_covers/16870114.png
http://cyberleninka.ru/article/n/primenenie-sunitiniba-v-realnoy-klinicheskoy-praktike-u-bolnyh-metastaticheskim-rakom-pochki